Drug Trial Radar · NCT04476043
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
209
Actual
Start
Aug 25, 2020
Primary completion
Dec 15, 2021
Study completion Aug 16, 2023
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).
Conditions
- Hidradenitis Suppurativa
- Acne Inversa
Interventions
INCB054707Drug
Oral; Tablet
PlaceboDrug
Oral; Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16Time frame: Baseline; Week 16
Locations
40 sites in 6 countries. Site status is shown where the registry gives one.
Investigative Site 005
Hoover, Alabama
Investigative Site 003
Gilbert, Arizona
Investigative Site 011
Phoenix, Arizona
Investigative Site 014
Fountain Valley, California
Investigative Site 010
Fremont, California
Investigative Site 012
Huntington Beach, California
Investigative Site 022
Newbury Park, California
Investigative Site 009
Sacramento, California
Investigative Site 025
Cromwell, Connecticut
Investigative Site 015
Coral Gables, Florida
Investigative Site 021
Miami, Florida
Investigative Site 006
Tampa, Florida
Investigative Site 001
Tampa, Florida
Investigative Site 016
Atlanta, Georgia
Investigative Site 002
West Lafayette, Indiana
Investigative Site 027
Baton Rouge, Louisiana
Investigative Site 023
New Orleans, Louisiana
Investigative Site 013
Boston, Massachusetts
Investigative Site 004
Fort Gratiot, Michigan
Investigative Site 019
St Louis, Missouri
Investigative Site 026
The Bronx, New York
Investigative Site 008
Chapel Hill, North Carolina
Investigative Site 017
Winston-Salem, North Carolina
Investigative Site 007
Hershey, Pennsylvania
Investigative Site 018
Bellaire, Texas
Investigative Site 101
Calgary, Alberta, Canada
Investigative Site 102
Calgary, Alberta, Canada
Investigative Site 304
Nantes, France
Investigative Site 403
Berlin, Germany
Investigative Site 401
Bochum, Germany
Investigative Site 405
Dessau, Germany
Investigative Site 406
Dresden, Germany
Investigative Site 404
Erlangen, Germany
Investigative Site 402
Frankfurt am Main, Germany
Investigative Site 552
Rzeszów, Poland
Investigative Site 551
Wroclaw, Poland
Investigative Site 553
Wroclaw, Poland
Investigative Site 703
Granada, Spain
Investigative Site 702
Madrid, Spain
Investigative Site 701
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.